STABLE HIGH CONCENTRATION STRONTIUM COMPOUNDS AND FORMULATIONS FOR TOPICAL APPLICATION
The disclosure herein relates to high concentration strontium compounds. The high concentrations are achievable through the use of a specialized polymer. More specifically, the polymers form a three dimensional structure having a hydrophilic interior and hydrophobic exterior.
1 . A topical formulation, comprising:
from 8 wt. % to 12 wt. % elemental strontium in a form of a strontium moiety; and
from 0.5 wt. % to 1.5 wt. % of a polyacrylate crosspolymer-6 amphiphilic polymer,
wherein the topical formulation has a pH of 2 to 5, and a hydrophilic-lipophilic balance of about 9 to about 11, wherein the hydrophilic-lipophilic balance is defined as 20×M h /M, where M h is defined as a molecular mass of a hydrophilic portion of the polymer, and M defined as is a molecular mass of the polymer as a whole.
2 . The topical formulation of claim 1 , wherein the polyacrylate crosspolymer-6 amphiphilic polymer is 70% to 80% hydrophobic and has a hydrophilic tail.
3 . The topical formulation of claim 1 , wherein the polyacrylate crosspolymer-6 amphiphilic polymer forms three dimensional structures in the topical formulation that are roughly spherical or like a flattened sphere in shape, the three dimensional structures having an exterior and an interior, wherein the exterior is mainly hydrophilic and the interior is mainly hydrophilic, and wherein a diameter of the three dimensional structures is less than 2 micrometers.
4 . The topical formulation of claim 1 , having a viscosity of 1000 centipoise to 25000 centipoise.
5 . The topical formulation of claim 1 , having a viscosity of 1000 centipoise to 10000 centipoise.
6 . The topical formulation of claim 1 , wherein the strontium moiety is a strontium salt selected from the group consisting of strontium nitrate, strontium chloride, strontium chloride hexahydrate, strontium hydroxide, and strontium lactate.
7 . The topical formulation of claim 1 , wherein the strontium moiety is strontium nitrate or strontium chloride.
8 . A method of manufacturing a topical formulation, comprising:
wetting a polyacrylate crosspolymer-6 polymer in an oil phase;
dissolving a strontium moiety into an aqueous phase; and
mixing at high speed the wetted polyacrylate crosspolymer-6 polymer and the dissolved strontium moiety to create a stable emulsion, whereby a topical formulation is obtained, the topical formulation comprising from 8 wt. % to 12 wt. % elemental strontium in a form of the strontium moiety, and from 0.5 wt. % to 1.5 wt. % of the polyacrylate crosspolymer-6 amphiphilic polymer, wherein the topical formulation has a pH of 2 to 5, and a hydrophilic-lipophilic balance of about 9 to about 11, wherein the hydrophilic-lipophilic balance is defined as 20×M h /M, where M h is defined as a molecular mass of a hydrophilic portion of the polymer, and M defined as is a molecular mass of the polymer as a whole.
9 . The method of claim 8 , wherein the polyacrylate crosspolymer-6 polymer is mainly hydrophobic.
10 . A method of treating peripheral neuropathic pain, comprising:
administering to a patient in need thereof a therapeutically effective amount of the topical formulation of claim 1 .
11 . The method of claim 10 , wherein the pain is due to a condition selected from the group consisting of an insect bite, a thermal burn, an ionizing radiation, an exposure to a chemical, a surgical wound, a nerve compression, or a viral infection.
12 . The method of claim 11 , wherein the viral infection is due to Herpes varicella zoster virus.
13 . The method of claim 11 , wherein the viral infection is due to human immunodeficiency virus.
14 . The method of claim 10 , wherein the pain is due to a condition selected from the group consisting of post herpetic neuralgia, diabetic neuropathy, or a side effect of use of a drug.
15 . The method of claim 14 , wherein the drug is used to treat HIV.